SQUARE

e-

SQUARE

 
Healthcare online Keeping you up-to-date
VOL.  6     ISSUE:  5    May 29, 2008 Medical Services Department

SQUARE Pharmaceuticals Ltd.

Features

EDITORIAL TEAM

OMAR AKRAMUR RAB

MBBS, FCGP, FIAGP,

P G Dip. Business Management

MAHFUZUR RAHMAN, MBBS

 

EDITORIAL

Dear Doctor,

Hope you are enjoying this online healthcare bulletin.

Our current issue focused on some interesting features like -

"Thyroid Risk !", "Sleep Alert !", "New Method !", "Biomarker For

 Prostate !",  "Powerful HIV Drug !", "Acrylamide Alert !".

In our regular feature, we have some new products information of SQUARE Pharmaceuticals Ltd. as well.

We will appreciate your feedback !

Click on to reply mode.

Yours sincerely,

 

Editorial Team

Reply Mode      : e-square@squaregroup.com

The views expressed in this publication do not necessarily reflect those of its editor or SQUARE Pharmaceuticals Ltd.

 Thyroid Risk !

 Thyroid Hormone Linked to Heart Disease

Even so-called normal levels of the thyroid hormone known as thyrotropin may be putting women at risk for heart disease. New research out of Norway suggests women with increasing levels of the hormone, even when those levels fall within the normal range, may be more likely to experience an adverse cardiac event like a heart attack. Investigators followed about 17,000 women and 8,000 men. During the study, 228 women and 183 men died of coronary heart disease. The vast majority of both groups -- 192 women and 182 men -- had thyrotropin levels within the clinical reference range and these levels were linked to coronary heart disease mortality. However, the finding was strong enough to be statistically significant only in the women. “This study shows that coronary heart disease mortality increases in women with increasing levels of thyrotropin within the reference range,” the authors were quoted as saying. “These results indicate that relatively low but clinically normal thyroid function may increase the risk of fatal coronary heart disease.” The investigators note other studies have associated thyrotropin levels with blood pressure, body mass index and cholesterol levels -- all factors that can lead to heart disease when they are elevated.

SOURCE: Ivanhoe Newswire, May 2008

Return to top

 Sleep Alert !

Sleep, Too Much Or Too Little

Sleeping more or less than the recommended seven or eight hours a night can put someone  at risk for metabolic syndrome -- a group of conditions like high cholesterol and high blood pressure that are closely linked to heart disease. In a new study of about 1,200 people between the ages of 30 and 54, researchers from the University of Pittsburgh found those who slept less than six hours a night or more than eight hours a night were about 45 percent more likely to have the condition. Short sleepers, however, were much more prevalent among the group, accounting for about 20 percent of the total. Long sleepers were less common, making up just eight percent of the group. The link between metabolic syndrome and sleep duration was strongest in the short sleepers. Overall, they were nearly twice as likely as normal sleepers to be diagnosed with the condition.

SOURCE:  Sleep, May 2008

Return to top

 
 
 New Method !

New Method to Create Vaccines

Scientists say they may have a new way to quickly and effectively create vaccines. The research could revolutionize the way vaccines are made now. When an infection is in the body, the immune system goes to work manufacturing antibodies to fight it. Most of the antibodies have no effect, but a few will bond to the invader and replicate to fight the enemy. In the past, scientists had to take a needle in a haystack approach to determine which antibodies will work to fight infections. Now, a new process could change that. Researchers from Oklahoma Medical Research Foundation and Emory University have found a way to identify and clone human antibodies specifically tailored to fight infection. The new process develops a “smart bomb” for the immune system. Researchers isolated antibody-secreting cells from people who have received the influenza vaccine, then cloned the antibody genes from these cells. This research is aimed at combating influenza, but could be used to create treatments for any condition that has a vaccine -- like smallpox or anthrax. Study authors say the technology cold serve as a therapy for someone who is already infected. It could also be the key to fighting diseases like multiple sclerosis and cancer. Scientists are currently working on making more antibodies from other infections.

SOURCE: Nature, May 2008

Return to top

 
 
 Biomarker For Prostate !

Biomarker Spots Lesions Likely to Progress to Prostate Cancer

Spanish researchers report they may have found a way to tell which suspicious prostate lesions are likely to develop into cancer. The findings show a link between high-grade prostatic intraepithelial neoplasia (HG-PIN) lesions and the PTOV1 gene. The more PTOV1 the lesion expresses, the more likely cancer will develop. The report also backs the reverse -- that the lack of PTOV1 means a reduced risk of prostate cancer. PTOV1 is a protein that researchers don't fully understand the function of, but they have previously found too much of it appears to promote the spread of cancer cells. If subsequent studies confirm PTOV1 as a biomarker for prostate cancer, it could help men with the lesions avoid repeated needle biopsies. "Those patients with a high PTOV1 score should undergo an immediate repeat biopsy," stated by a researcher at the Vall d'Hebron Hospital Research Institute in Barcelona. But those with low PTOVI may not need to receive future "annoying and useless" biopsies, the researcher added. HG-PIN, while present in most cancerous prostates, is a pre-malignant lesion and, given its association with other cancers, it is often repeatedly biopsied when found. Past studies have put the average risk of cancer being diagnosed in a HG-PIN biopsy at between 20 percent and 30 percent, the researchers said. However, none of these studies were to tell which lesions would progress to cancer, according to the researchers.

SOURCE: HealthDay News, May 2008

Return to top

 
 
 Powerful HIV Drug !

Most Powerful HIV Drug

One of the most commonly prescribed triple-drug combinations for HIV is also the most effective, but a separate two-drug regime may work as well, new research reveals. The study looked at nucleoside reverse transcriptase inhibitors (NRTIs), one of the first class of HIV drugs approved by the Food and Drug Administration (FDA), as well as a two-drug regimen not including NRTIs, which are known to cause serious side effects in some patients. Researchers studied 753 participants and found the three-drug regime combining efavirenz and NRTI therapy suppressed the virus more effectively than the drug combination of lopinavir-ritonavir plus NRTI. During the almost two-year study, 24 percent of the patients in the efavirenz group had their HIV return to detectable levels, compared to 33 percent in the lopinavir-ritonavir group. They also found combining lopinavir-ritonavir and efavirenz had a similar level of effectiveness to the triple-drug regimens containing NRTIs. Twenty-seven percent of participants in that group had their HIV return to detectable levels. Immune responses improved in all three treatment regimens. “Although all three regimens were well-tolerated and effective, our results showed that efavirenz with NRTIs should still be considered the gold standard regimen for initial HIV treatment.” According to the lead author of the study and an associate professor of medicine at the University of Pittsburgh School of Medicine, was quoted as saying. “The results from the NRTI-sparing regimen have given us valuable reassurance that we can utilize a two-drug therapy regimen based on lopinavir-ritonavir plus efavirenz for patients who are unable to take NRTI due to side effects,” he added.

SOURCE: Ivanhoe Newswire, May 2008

Return to top

 
 
 Acrylamide Alert !

Acrylamide Raises Kidney Cancer Risk

Consuming large amounts of acrylamide, a chemical commonly found in French fries, cakes, snacks and even coffee, appears to raise the risk of kidney cancer, especially in smokers, Dutch researchers report. "Ours is the first report of a positive association between dietary acrylamide intake and renal cell cancer," said the researcher at Maastricht University in the Netherlands. Studies of the chemical have been ongoing since 1994, when the International Agency for Research on Cancer classified the chemical as a probable human carcinogen. Experts thought the main exposure was environmental, through cigarette smoke and, to a lesser extent, cosmetics. But in 2002, Swedish scientists reported the presence of the chemical in carbohydrate-rich foods produced at high temperatures, including French fries and potato chips. Studies of the chemical's link to various cancers have yielded mixed results. The Dutch research team took data from the Netherlands Cohort Study on diet and cancer, which includes more than 120,000 men and women, aged 55 to 69. They followed them for more than 13 years, looking at all the cases of kidney, bladder and prostate cancers. They took a random sample of 5,000 people to look at their dietary habits. The average intake of acrylamide from the diet was 21.8 micrograms -- a little less than what is included in a 2.5-ounce serving of French fries. Those who took in the most -- averaging 40.8 micrograms a day -- had a 59 percent higher risk of kidney cancer (but not the other cancers) than those consuming the least. For most people, coffee was the major source of the chemical. However, a popular snack, Dutch spiced cake, was the main source of the chemical for those consuming the most. The relationship was found to be stronger for smokers. For each additional 10 micrograms ingested of the chemical, kidney cancer risk increased by 10 percent, the researchers found. Exactly how the acrylamide boosts cancer risk isn't known, but the hypothesis is that metabolites of the acrylamide cause DNA damage, according to the researcher. Limiting the consumption of foods containing the chemical is wise, the scientist said. "Also, in preparing food at home, fry potatoes at temperatures below 175 degrees Celsius and fry them to gold-yellow, not dark brown [the more brown, the more acrylamide]. The same goes for making toast and cookies", the researcher added.

SOURCE: HealthDay News, May 2008

Return to top

 
 

New Products of SQUARE Pharmaceuticals Ltd.

  Product Lumertam®
  Generic Name Artemether INN + Lumefantrine INN
  Strength 20 mg + 120 mg
  Dosage form Tablet
  Therapeutic Category Antimalarial
  Product Frabex®
Generic Name

Tranexamic acid BP

Strength

Capsule :Each capsule contains Tranexamic acid BP 500 mg

Injection:Each 5 ml inj. contains Tranexamic acid BP 500 mg

Dosage form Capsule & Injection
Therapeutic Category Antifibrinolytics
  Product Isovent 100
  Generic Name Misoprostol INN
  Strength

100 mcg

  Dosage form Tablet
  Therapeutic Category Labor inducer

Return to top

 

Copyright © 2008 SQUARE Pharmaceuticals Ltd. All rights reserved.